Table 2.
Comparison of prevalence of metabolic syndrome and its components among three groups
| Group 0 (n = 274) |
NAFLD |
||
| Group 1 (n = 436) | Group 2 (n = 151) | ||
| Age (yr) | 10.36 ± 2.15 | 10.59 ± 1.85 | 10.40 ± 2.28 |
| Sex (M/F) | 187/87 | 305/131 | 106/45 |
| Tanner stage (T1/T2–4) | 130/144 | 209/227 | 74/77 |
| BMI | 26.88 ± 3.19 | 28.78 ± 3.96a | 28.85 ± 3.69a |
| Hypertension | 68 (24.82) | 180 (41.28)a | 73 (48.34)a |
| Dyslipidemia | 42 (15.32) | 204 (46.78)a | 116 (76.82)ac |
| Impaired fasting glucose | 5 (1.82) | 30 (6.88) | 20 (13.24)ac |
| IGT | 13 (4.74) | 38 (8.72) | 18 (11.92)a |
| Diabetes | 0 (0.00) | 5 (1.14) | 7 (4.63)ac |
| MS | 33 (12.04) | 128 (29.36)a | 60 (39.74)ac |
a
P < 0.05 vs group 0;
c
P < 0.05, group 1 vs group 2. Data are expressed as percentage, mean ± SD. NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index; IGT: Impaired glucose tolerance; MS: Metabolic syndrome.